DK2699233T3 - Partikulært materiale og cellulært toksin til anvendelse til behandling af en solid tumor - Google Patents

Partikulært materiale og cellulært toksin til anvendelse til behandling af en solid tumor Download PDF

Info

Publication number
DK2699233T3
DK2699233T3 DK12774165.0T DK12774165T DK2699233T3 DK 2699233 T3 DK2699233 T3 DK 2699233T3 DK 12774165 T DK12774165 T DK 12774165T DK 2699233 T3 DK2699233 T3 DK 2699233T3
Authority
DK
Denmark
Prior art keywords
particulate material
stabiliser
steric
nanoparticles
polymeric segment
Prior art date
Application number
DK12774165.0T
Other languages
English (en)
Inventor
Brian Stanley Hawkett
Trevor William Hambley
Nicole Sarah Bryce
Thi Thuy Binh Pham
Nirmesh Jain
Original Assignee
Univ Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011901495A external-priority patent/AU2011901495A0/en
Application filed by Univ Sydney filed Critical Univ Sydney
Application granted granted Critical
Publication of DK2699233T3 publication Critical patent/DK2699233T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (12)

1. Partikulært materiale og cellulært toksin til anvendelse til behandling af en solid tumor, hvor det partikulære materiale er i form af en dispersion i et væskeformigt bæremiddel, hvilket partikulære materiale opretholdes i den dispergerede tilstand ved hjælp af en stabilisator; hvor stabilisatoren er en sterisk stabilisator, der omfatter et sterisk stabiliserende polymert segment og en forankringsdel ; hvor forankringsdelen forankrer stabilisatoren til det partikulære materiale og er forskellig fra den resterende del af stabilisatoren; hvor det steriske stabiliserende polymere segment er opløseligt i det væskeformige bæremiddel og omfatter en terminal ionisk funktionel gruppe, især hvor den ioniske funktionelle gruppe er en kation; hvor det partikulære materiale ligger i størrelsesintervallet fra ca. 10 nm til ca. 350 nm; hvor det partikulære materiale og cellulære toksin penetrerer den solide tumor; hvor det partikulære materiale og cellulære toksin administreres samtidigt i to separate formuleringer; og hvor det cellulære toksin er enten et cytostatisk eller cytosidt middel udvalgt fra gruppen, der består af doxorubicin, mitoxantron, cisplatin, paclitaxel og 5-FU.
2. Partikulært materiale og cellulært toksin til anvendelse ifølge krav 1, hvor det steriske stabiliserende polymere segment omfatter en terminal ionisk funktionel gruppe, hvor den ioniske funktionelle gruppe er en kation.
3. Partikulært materiale og cellulært toksin til anvendelse ifølge et hvilket som helst af kravene 1 og 2, hvor det steriske stabiliserende polymere segment af stabilisatoren omfatter polymer udvalgt blandt poly(acrylamid), poly(ethylenoxid), poly(hydroxyethylacrylat), poly(N- isopropylacrylamid), poly(dimethylaminoethylmethacrylat), poly(vinylpyrrolidon) og copolymerer deraf.
4. Partikulært materiale og cellulært toksin til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor det forankrende polymere segment omfatter en eller flere carboxylsyregrupper, en eller flere phosphatgrupper, en eller flere phosphinatgrupper, en eller flere thiolgrupper, en eller flere thiocarbonylthiogrupper, en eller flere sulfonsyregrupper, ethoxysilylgrupper eller kombinationer deraf.
5. Partikulært materiale og cellulært toksin til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor stabilisatoren er en sterisk stabilisator, der omfatter et sterisk stabiliserende polymert segment og et forankrende polymert segment.
6. Partikulært materiale og cellulært toksin til anvendelse ifølge krav 5, hvor det ene eller begge af det steriske stabiliserende og forankrende polymere segment omfatter den polymeriserede rest af en eller flere etylenisk umættede monomerer.
7. Partikulært materiale og cellulært toksin til anvendelse ifølge et hvilket som helst af kravene 1 til 6, hvor stabilisatoren har en talgennemsnitlig molekylvægt (Mn) på mindre end 30.000.
8. Partikulært materiale og cellulært toksin til anvendelse ifølge et hvilket som helst af kravene 1 til 7, hvor det partikulære materiale er udvalgt blandt et metal, en metallegering, et metalsalt, et metalkompleks, en metaloxid, en uorganisk oxid, en radioaktiv isotop, en polymerpartikel og kombinationer deraf.
9. Partikulært materiale og cellulært toksin til anvendelse ifølge krav 8, hvor det partikulære materiale er udvalgt fra en gruppe, der består af jernoxid, guld, siliciumoxid og polystyren.
10. Partikulært materiale og cellulært toksin til anvendelse ifølge et hvilket som helst af kravene 1 til 9, hvor det partikulære materiale eller stabilisatoren er koblet til en ligand, hvilken ligand er rettet mod tumoren.
11. Partikulært materiale og cellulært toksin til anvendelse ifølge krav 1, hvor det partikulære materiale administreres ved hjælp af injektion.
12. Partikulært materiale og cellulært toksin til anvendelse ifølge et hvilket som helst af kravene 1 til 11, hvor det partikulære materiale administreres før det cellulære toksin; eller hvor de partikulære materialer og det cellulære toksin administreres samtidigt.
DK12774165.0T 2011-04-20 2012-04-20 Partikulært materiale og cellulært toksin til anvendelse til behandling af en solid tumor DK2699233T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161477382P 2011-04-20 2011-04-20
AU2011901495A AU2011901495A0 (en) 2011-04-20 A method of treatment and agents useful for same
AU2012900480A AU2012900480A0 (en) 2012-02-09 A method of treatment and agents useful for same
PCT/AU2012/000414 WO2012142669A1 (en) 2011-04-20 2012-04-20 A method for the treatment of a solid tumour

Publications (1)

Publication Number Publication Date
DK2699233T3 true DK2699233T3 (da) 2017-07-10

Family

ID=47040974

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12774165.0T DK2699233T3 (da) 2011-04-20 2012-04-20 Partikulært materiale og cellulært toksin til anvendelse til behandling af en solid tumor

Country Status (12)

Country Link
US (3) US20150037252A1 (da)
EP (1) EP2699233B1 (da)
JP (1) JP6038881B2 (da)
KR (1) KR20140022904A (da)
CN (1) CN104053432A (da)
AU (1) AU2012245080B2 (da)
CA (1) CA2833413C (da)
DK (1) DK2699233T3 (da)
ES (1) ES2629187T3 (da)
IL (1) IL228917A0 (da)
PT (1) PT2699233T (da)
WO (1) WO2012142669A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016270559B2 (en) 2015-06-04 2020-12-10 Crititech, Inc. Collection device and methods for use
CA3018989A1 (en) 2016-04-04 2017-10-12 Crititech, Inc. Methods for solid tumor treatment
JP2020523285A (ja) 2017-06-09 2020-08-06 クリチテック，インコーポレイテッド 抗腫瘍粒子の嚢胞内注入による上皮嚢胞の治療
WO2018231908A1 (en) 2017-06-14 2018-12-20 Crititech, Inc. Methods for treating lung disorders
US10428020B2 (en) * 2017-06-16 2019-10-01 The Boeing Company Antimicrobial compounds and nanostructures
RU2020110399A (ru) 2017-10-03 2021-11-09 Крититек, Инк. Местная доставка противоопухолевых частиц в комбинации с системной доставкой иммунотерапевтических агентов для лечения рака
ES2823927B2 (es) * 2019-11-07 2022-01-18 Beijing Enbiwo Biological Tech Co Ltd Composición en tamaño micrométrico y su uso como agente coadyuvante de alcaloides vegetales
WO2021097537A1 (en) 2019-11-21 2021-05-27 Ferronova Pty Ltd Magnetic tracer compositions
MX2019015508A (es) 2019-12-18 2021-06-21 Univ Guadalajara Nanopartículas para el tratamiento del cáncer.

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE156706T1 (de) * 1993-03-17 1997-08-15 Silica Gel Gmbh Superparamagnetische teilchen, verfahren zu ihrer herstellung und verwendung derselben
US5411730A (en) 1993-07-20 1995-05-02 Research Corporation Technologies, Inc. Magnetic microparticles
US6106866A (en) 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
DE19624426A1 (de) * 1996-06-19 1998-01-02 Christian Bergemann Magnetische Flüssigkeiten für den Transport von diagnostisch oder therapeutisch wirksamen Substanzen
DE19726282A1 (de) 1997-06-20 1998-12-24 Inst Neue Mat Gemein Gmbh Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US7217735B1 (en) 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
AU2002327179A1 (en) * 2001-06-07 2002-12-16 University Of Kentucky Research Foundation Nanoscintillation systems for aqueous-based liquid scintillation counting
WO2003040308A2 (en) 2001-07-27 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo
DE10144252A1 (de) * 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
GB2383534A (en) 2001-12-28 2003-07-02 Psimei Pharmaceuticals Plc Delivery of neutron capture elements for neutron capture therapy
JP3988469B2 (ja) 2002-01-25 2007-10-10 ソニー株式会社 半導体レーザ駆動回路
US20040082521A1 (en) 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
US20040038303A1 (en) 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
FR2840532B1 (fr) 2002-06-11 2005-05-06 Ethypharm Sa Nanocapsules lipidiques furtives, procede de preparation et utilisation comme vecteur de principes(s) actif(s)
GB0312309D0 (en) 2003-05-29 2003-07-02 Gaslini Children S Hospital G Targeted liposome
EP1651276A4 (en) * 2003-08-08 2009-05-06 Barnes Jewish Hospital EMULSION PARTICLES FOR IMAGING AND THERAPY AND USE METHOD THEREFOR
KR20050081092A (ko) 2004-02-12 2005-08-18 한국과학기술연구원 생체적합성 친수성 고분자를 포함하는 콜로이드계 조성물,제형 및 이들의 제조 방법
US7449196B2 (en) 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
US7348026B2 (en) 2004-10-05 2008-03-25 Hsing-Wen Sung Nanoparticles for targeting hepatoma cells
US20060280689A1 (en) 2005-04-22 2006-12-14 Intematix Corporation New MRI technique based on electron spin resonance and nitrogen endohedral C60 contrast agent
EA015781B1 (ru) 2005-10-21 2011-12-30 Панацея Биотек Лимитед Композиции для лечения рака
WO2007122956A1 (ja) * 2006-03-24 2007-11-01 Toto Ltd. 酸化チタン複合体粒子、その分散液、およびそれらの製造方法
US20090041673A1 (en) 2007-08-03 2009-02-12 Anygen Co., Ltd. Thermally Crosslinked Contrast Agents
WO2009031859A2 (en) * 2007-09-06 2009-03-12 Anygen Co., Ltd. Multi-functional complex for imaging and drug delivery
US20110104052A1 (en) * 2007-12-03 2011-05-05 The Johns Hopkins University Methods of synthesis and use of chemospheres
WO2009105671A2 (en) 2008-02-21 2009-08-27 Burnham Institute For Medical Research Methods and compositions related to peptides and proteins with c-terminal elements cross-reference to related applications
KR101638201B1 (ko) * 2008-05-16 2016-07-08 유니버시티 오브 시드니 투여 가능한 조성물
JP2010059143A (ja) * 2008-05-29 2010-03-18 Toto Ltd 複合体粒子
JP5531332B2 (ja) 2008-06-05 2014-06-25 株式会社島津製作所 新規な分子集合体、それを用いた分子イメージング用分子プローブ及び薬剤搬送システム用分子プローブ、並びに分子イメージングシステム及び薬剤搬送システム
JPWO2010016581A1 (ja) * 2008-08-08 2012-01-26 Toto株式会社 超音波癌治療促進剤

Also Published As

Publication number Publication date
US10376589B2 (en) 2019-08-13
US20150037252A1 (en) 2015-02-05
CA2833413C (en) 2020-09-22
IL228917A0 (en) 2013-12-31
AU2012245080B2 (en) 2015-06-25
EP2699233A1 (en) 2014-02-26
US20190365901A1 (en) 2019-12-05
US20180117160A1 (en) 2018-05-03
EP2699233A4 (en) 2014-10-22
ES2629187T3 (es) 2017-08-07
CA2833413A1 (en) 2012-10-26
WO2012142669A1 (en) 2012-10-26
NZ616780A (en) 2015-10-30
PT2699233T (pt) 2017-07-03
EP2699233B1 (en) 2017-03-29
JP6038881B2 (ja) 2016-12-07
JP2014511880A (ja) 2014-05-19
KR20140022904A (ko) 2014-02-25
AU2012245080A1 (en) 2013-04-11
CN104053432A (zh) 2014-09-17

Similar Documents

Publication Publication Date Title
DK2699233T3 (da) Partikulært materiale og cellulært toksin til anvendelse til behandling af en solid tumor
Han et al. A nanomedicine approach enables co-delivery of cyclosporin A and gefitinib to potentiate the therapeutic efficacy in drug-resistant lung cancer
Agnello et al. Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors
Yao et al. Multifunctional sharp pH-responsive nanoparticles for targeted drug delivery and effective breast cancer therapy
Ke et al. Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy
Li et al. Albumin-stabilized layered double hydroxide nanoparticles synergized combination chemotherapy for colorectal cancer treatment
Du et al. Combined phycocyanin and hematoporphyrin monomethyl ether for breast cancer treatment via photosensitizers modified Fe3O4 nanoparticles inhibiting the proliferation and migration of MCF-7 cells
Bouzo et al. Sphingomyelin nanosystems loaded with uroguanylin and etoposide for treating metastatic colorectal cancer
Joshi et al. Inhibition of cancer cell metastasis by nanotherapeutics: current achievements and future trends
Shi et al. Fabrication and characterization of a folic acid-bound 5-fluorouracil loaded quantum dot system for hepatocellular carcinoma targeted therapy
Gholami et al. A comprehensive perspective of trastuzumab-based delivery systems for breast cancer treatment
Duan et al. Mnox Nanoenzyme Armed CAR‐NK Cells Enhance Solid Tumor Immunotherapy by Alleviating the Immunosuppressive Microenvironment
CN113018263A (zh) 载plk1抑制剂的聚合物囊泡药物及其制备方法与应用
Yu et al. Lenalidomide Promotes Melarsoprol-Activated cGAS-STING-Mediated Immunotherapy for Hepatocellular Carcinoma via Attenuating TNF-α Activity
JP2021020876A (ja) がん療法用のｔ−ＰＡ含有ポリマー組成物
Sugumaran et al. Colloidal nanocarriers as versatile targeted delivery systems for cervical cancer
Cheng et al. Biotin-Conjugated Upconversion KMnF3/Yb/Er Nanoparticles for Metabolic Magnetic Resonance Imaging of the Invasive Margin of Glioblastoma
Zhao et al. Low-dose pleiotropic radiosensitive nanoformulations for three-pronged radiochemotherapy of hypoxic brain glioblastoma under BOLD/DWI monitoring
CN114099469A (zh) 一种复合纳米药物载体及其制备方法和应用
NZ616780B2 (en) A method for the treatment of a solid tumour
Liu et al. Long-circulating gambogic acid-loaded nanodiamond composite nanosystem with inhibition of cell migration for tumor therapy
Huang et al. Chiral coordination polymer nanowires boost radiation-induced in situ tumor vaccination
Luo et al. Polymers based on phenyl boric acid in tumor-targeted therapy
US12128041B2 (en) Nanoparticles for delivering drug, whose surface is modified with peptide for targeting brain cancer, preparation method thereof and use thereof
US20220323432A1 (en) Nanoparticles for delivering drug, whose surface is modified with peptide for targeting brain cancer, preparation method thereof and use thereof